Subscribe To
Coherus presents data from next-generation immuno-oncology programs at 38th annual meeting of society for immunotherapy of cancer (sitc)
– Data demonstrate distinct IL-27-mediated expression of genes associated with immune suppression in vitro, supporting ongoing clinical development ...
November 3, 2023, 12:30 pm
Angle technolgy could help provide a more targeted approach to head and neck cancer
ANGLE plc, a leading company in liquid biopsy technology, has unveiled promising research findings that could help transform the treatment of head and...
October 25, 2023, 2:53 am
Lisata therapeutics announces first patient treated in the cholangiocarcinoma cohort of the bolster trial of lsta1, a novel tumor-targeting and penetrating peptide
Phase 2a double-blind, placebo-controlled, multi-center, randomized study evaluating LSTA1 in combination with standard-of-care versus standard-of-car...
October 24, 2023, 12:00 pm
Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...
October 23, 2023, 5:00 am
Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...
October 23, 2023, 5:00 am
Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...
October 23, 2023, 5:00 am
Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...
October 23, 2023, 5:00 am
Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...
October 23, 2023, 5:00 am
Libtayo® (cemiplimab) neoadjuvant treatment demonstrates encouraging event-free survival in patients with resectable cutaneous squamous cell carcinoma (cscc)
89% estimated event-free survival at one year among patients with stage II to IV resectable CSCC who received Libtayo prior to surgery in a Phase 2 tr...
October 21, 2023, 12:48 pm
Akoya biosciences announces peer-reviewed publication using ultrahigh-plex spatial phenotyping of head and neck cancer to identify distinct immune and metabolic signatures
MARLBOROUGH, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today anno...
October 17, 2023, 2:22 pm
Regeneron to showcase progress from innovative oncology portfolio in several difficult-to-treat cancers at esmo
Event-free survival of investigational use of Libtayo® (cemiplimab) in neoadjuvant cutaneous squamous ...
October 15, 2023, 10:05 pm
Onconova therapeutics to present a late-breaking abstract on rigosertib at the 2023 eadv congress
NEWTOWN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage bi...
September 28, 2023, 12:00 pm
Nuvectis: early stage company that's low on cash
Nuvectis is developing precision medicines for cancer patients, with lead asset NXP800 targeting ARID1a-mutated ovarian cancer. Preclinical trials hav...
September 6, 2023, 8:03 am
Merck and eisai cull late-stage study for head and neck cancer therapy
Merck & Co Inc (NYSE:MRK) and research partner Eisai said they are halting a late-stage trial that used a combination of drugs to treat a type of head...
August 25, 2023, 7:58 am
Replimune: q4 2023 data readouts of rp1 makes this a must watch
Replimune Group, Inc. results from the registration-directed phase 2 CERPASS trial, using RP1 + Libtayo for the treatment of patients with cutaneous <...
August 14, 2023, 5:28 pm
Ipo update: adlai nortye readies $72 million u.s. ipo
Adlai Nortye Ltd. has filed for a $72 million IPO for its cancer drug development. The firm's lead candidate, AN2025, is in Phase 2 and Phase 3 trials...
August 11, 2023, 2:16 pm
Checkpoint: pdufa date catalyst makes this a must watch
A PDUFA date of January 3, 2024 has been established by which FDA will decide upon by then whether or not cosibelimab should be approved for the treat...
August 1, 2023, 7:01 pm
Checkpoint therapeutics: cosibelimab data bolsters case for dual-approval in cscc
Checkpoint Therapeutics announced updated, longer-term data for cosibelimab from their pivotal trial in locally advanced and metastatic cutaneous
July 30, 2023, 4:19 am
Replimune: the rise of oncolytic virus therapies in cancer treatment
The company's RPx platform, featuring RP1, RP2, and RP3, showcases a comprehensive and innovative approach to cancer treatment. Top-line results from ...
July 9, 2023, 1:22 am
Castle biosciences stock soars on medicare reversal; data presentation
Castle Biosciences, Inc shares surged 55% to $20.64 on Friday after Novitas, a regional Medicare administrative contractor, reversed its draft policy...
July 7, 2023, 3:24 pm
